{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:30:02Z","timestamp":1791916202044,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.yebeh.2021.108514","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T15:32:17Z","timestamp":1641396737000},"page":"108514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners"],"prefix":"10.1016","volume":"127","author":[{"given":"Owen S.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edmund J.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Gidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.108514_b0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","article-title":"Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome","volume":"47","author":"Hussain","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108514_b0010","unstructured":"U.S. Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms (accessed January 21, 2021)."},{"key":"10.1016\/j.yebeh.2021.108514_b0015","unstructured":"U.S. Food and Drug Administration. FDA approves new indication for drug containing an active ingredient derived from cannabis to treat seizures in rare genetic disease 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare (accessed January 21, 2021)."},{"key":"10.1016\/j.yebeh.2021.108514_b0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex A placebo-controlled randomized clinical trial supplemental content CME Quiz at jamacmelookup.com","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.108514_b0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108514_b0030","unstructured":"GW Pharmaceuticals plc. EPIDIOLEX\u00ae (cannabidiol) [package insert]. US Food and Drug Administration Website 2020:1\u201336."},{"key":"10.1016\/j.yebeh.2021.108514_b0035","unstructured":"Bodie A, Green V, Johnson R, Sacco L. FDA Regulation of Cannabidiol (CBD) Consumer Products: Overview and Considerations for Congress (R46189). 2020."},{"key":"10.1016\/j.yebeh.2021.108514_b0040","unstructured":"Drug Enforcement Administration D of J. schedules of controlled substances: placement in schedule V of Certain FDA-approved drugs containing cannabidiol; corresponding change to permit requirements. Final order. Federal Register 2018;83:48950\u20133."},{"key":"10.1016\/j.yebeh.2021.108514_b0045","unstructured":"Idaho Office of Drug Policy. Epidiolex\u00ae Fact Sheet. Idaho Office of Drug Policy 2018:1\u20132. https:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6720a5.htm (accessed July 2, 2021)."},{"issue":"9","key":"10.1016\/j.yebeh.2021.108514_b0050","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.mayocp.2019.01.003","article-title":"Clinicians' guide to cannabidiol and hemp oils","volume":"94","author":"VanDolah","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.yebeh.2021.108514_b0055","doi-asserted-by":"crossref","first-page":"107268","DOI":"10.1016\/j.yebeh.2020.107268","article-title":"Expectations and knowledge of cannabidiol therapy for childhood epilepsy \u2014 A German caregiver survey","volume":"111","author":"Klotz","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108514_b0060","doi-asserted-by":"crossref","unstructured":"Leszko M, Meenrajan S. Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer\u2019s disease. Complement Ther Med 2021;57. https:\/\/doi.org\/10.1016\/j.ctim.2021.102660.","DOI":"10.1016\/j.ctim.2021.102660"},{"issue":"7","key":"10.1016\/j.yebeh.2021.108514_b0065","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1080\/10826084.2020.1729201","article-title":"CBD (cannabidiol) product attitudes, knowledge, and use among young adults","volume":"55","author":"Wheeler","year":"2020","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.yebeh.2021.108514_b0070","doi-asserted-by":"crossref","first-page":"107102","DOI":"10.1016\/j.yebeh.2020.107102","article-title":"Attitudes and knowledge about cannabis and cannabis-based therapies among US neurologists, nurses, and pharmacists","volume":"109","author":"Szaflarski","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108514_b0075","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA - J Am Med Assocation"},{"key":"10.1016\/j.yebeh.2021.108514_b0080","first-page":"1","article-title":"The advisability and feasibility of developing USP standards for medical cannabis","volume":"42","author":"Giancaspro","year":"2015","journal-title":"Stimuli"},{"key":"10.1016\/j.yebeh.2021.108514_b0085","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1021\/acs.jnatprod.9b01200","article-title":"Cannabis inflorescence for medical purposes: USP considerations for quality attributes","volume":"83","author":"Sarma","year":"2020","journal-title":"J Nat Prod"},{"key":"10.1016\/j.yebeh.2021.108514_b0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jpba.2017.07.021","article-title":"Qualitative and quantitative measurement of cannabinoids in cannabis using modified HPLC\/DAD method","volume":"146","author":"Patel","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.yebeh.2021.108514_b0095","unstructured":"USP-NF \u30081225\u3009 Validation of compendial procedures. United States Pharmacopeia and National Formulary (USP 43-NF 38) 2017. https:\/\/online.uspnf.com\/uspnf\/document\/1_GUID-E2C6F9E8-EA71-4B72-A7BA-76ABD5E72964_4_en-US?source=TOC#C1225S8 (accessed August 4, 2021)."},{"key":"10.1016\/j.yebeh.2021.108514_b0100","first-page":"1","article-title":"Strength and stability testing for compounded preparations","author":"Allen","year":"2014","journal-title":"US Pharmacopeia"},{"key":"10.1016\/j.yebeh.2021.108514_b0105","article-title":"FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns","author":"U.S. Food and Drug Administration","year":"2019","journal-title":"FDA US Food and Drug Administration"},{"key":"10.1016\/j.yebeh.2021.108514_b0110","unstructured":"U.S. Food and Drug Administration. Warning letters and test results for cannabidiol-related products | FDA. FDA Public Health Focus 2021. https:\/\/www.fda.gov\/news-events\/public-health-focus\/warning-letters-and-test-results-cannabidiol-related-products (accessed August 3, 2021)."},{"key":"10.1016\/j.yebeh.2021.108514_b0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/19390211.2020.1766634","article-title":"Content versus label claims in cannabidiol (CBD)-containing products obtained from commercial outlets in the State of Mississippi","volume":"17","author":"Gurley","year":"2020","journal-title":"J Diet Suppl"},{"key":"10.1016\/j.yebeh.2021.108514_b0120","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","article-title":"Cannabidiol adverse effects and toxicity","volume":"17","author":"Huestis","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.yebeh.2021.108514_b0125","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/epi.16674","article-title":"Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs","volume":"61","author":"Patsalos","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108514_b0130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/jcm8070989","article-title":"Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use","volume":"8","author":"Brown","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.yebeh.2021.108514_b0135","doi-asserted-by":"crossref","unstructured":"Lachenmeier DW, Habel S, Fischer B, Herbi F, Zerbe Y, Bock V, et al. Are side effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? [version 3; peer review: 2 approved, 1 approved with reservations] 2019. https:\/\/doi.org\/10.12688\/f1000research.19931.1.","DOI":"10.12688\/f1000research.19931.1"},{"key":"10.1016\/j.yebeh.2021.108514_b0140","article-title":"Urine drug tests: Ordering and interpretation","volume":"99","author":"Kale","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.yebeh.2021.108514_b0145","doi-asserted-by":"crossref","unstructured":"Barrus DG, Capogrossi KL, Cates SC, Gourdet CK, Peiper NC, Novak SP, et al. RTI Press tasty THC: promises and challenges of cannabis edibles occasional paper 2016. https:\/\/doi.org\/10.3768\/rtipress.2016.op.0035.1611.","DOI":"10.3768\/rtipress.2016.op.0035.1611"},{"key":"10.1016\/j.yebeh.2021.108514_b0150","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.2174\/138161212802884780","article-title":"Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers","volume":"18","author":"Martin-Santos","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.yebeh.2021.108514_b0155","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/jama.2020.21218","article-title":"Effect of cannabidiol and ?9-tetrahydrocannabinol on driving performance: a randomized clinical trial","volume":"324","author":"Arkell","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108514_b0160","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s40501-020-00202-2","article-title":"Cannabis and the developing adolescent brain","volume":"7","author":"Fischer","year":"2020","journal-title":"Curr Treat Options Psychiatry"},{"key":"10.1016\/j.yebeh.2021.108514_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-018-0882-y","article-title":"Cannabis for the treatment of epilepsy: an update","volume":"18","author":"Gaston","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108514_b0170","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/JCP.0000000000001089","article-title":"The potential for pharmacokinetic interactions between cannabis products and conventional medications","volume":"39","author":"Qian","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2021.108514_b0175","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/15226514.2020.1774504","article-title":"Promises and potential of in situ nano-phytoremediation strategy to mycorrhizo-remediate heavy metal contaminated soils using non-food bioenergy crops (Vetiver zizinoides & Cannabis sativa)","volume":"22","author":"Khan","year":"2020","journal-title":"Int J Phytorem"},{"key":"10.1016\/j.yebeh.2021.108514_b0180","first-page":"45","article-title":"Cannabinoid, terpene, and heavy metal analysis of 29 over-the-counter commercial veterinary hemp supplements","volume":"11","author":"Wakshlag","year":"2020","journal-title":"Veter Med Res Rep"},{"key":"10.1016\/j.yebeh.2021.108514_b0185","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/bcp.13695","article-title":"Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects","volume":"84","author":"Dryburgh","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108514_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.571832","article-title":"Cannabis contaminants limit pharmacological use of cannabidiol","volume":"11","author":"Montoya","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.yebeh.2021.108514_b0195","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/j.1360-0443.2008.02230.x","article-title":"Cannabis potency and contamination: A review of the literature","volume":"103","author":"McLaren","year":"2008","journal-title":"Addiction"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:43:03Z","timestamp":1761504183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021007757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":39,"alternative-id":["S1525505021007757"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108514","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108514"}}